New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:47 EDTMYL, PFE, LMCA, BF.A, VTR, FOXA, MHFI, ACT, TWC, BEAM, DTV, TGT, CAKFY, NDAQ, VRX, CHTR, BF.B, HCN, SHLD, MCKOn the Fly: Periodicals Wrap
WSJ: DirecTV (DTV) wants Weather Channel fee reduction as apps take hold...Brown-Forman (BF.A, BF.B) may benefit from Beam (BEAM) deal...REUTERS: Malone (LMCA, CHTR) seeks consolidation in Time Warner Cable (TWC) bid...Pfizer's (PFE) generics unit attracts several suitors (VRX, ACT, MYL)...Nasdaq (NDAQ), S&P (MHFI) interested in acquisitions to grow index businesses...BLOOMBERG: McKesson (MCK) considers JV following failure of Celesio (CAKFY) bid...Fox (FOXA) won't participate in network TV’s pilot season...Sears (SHLD) may be cut by S&P...OTHER NEWS: Target's (TGT) problems may benefit security firms, NY Times reports...Ventas (VTR) and Health Care REIT (HCN) held talks, dealReporter reports.
News For B;BEAM;LMCA;CHTR;TWC;PFE;VRX;ACT;MYL;NDAQ;MHFI;MCK;CAKFY;FOXA;SHLD;TGT;VTR;HCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 9, 2014
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information
06:14 EDTACTAllergan price target raised to $245 from $210 at Citigroup
Subscribe for More Information
December 8, 2014
15:49 EDTMHFISEC seeks to suspend S&P from rating CMBS, Bloomberg reports
In what would be the SEC's toughest action yet against a major credit rater, the commission is seeking to suspend Standard & Poor’s from rating commercial mortgage bonds, but its parent company McGraw Hill Financial remains in talks over a possible settlement, according to Bloomberg, citing a person with knowledge of the matter. Shares of McGraw Hill Financial are down 1.6% to $92.21 following Bloomberg's report. Reference Link
15:42 EDTMHFISEC seeks to suspend S&P from rating CMBS, Bloomberg says
Subscribe for More Information
14:36 EDTTWCTime Warner Cable CEO reports strong trends in October, November, says UBS
Subscribe for More Information
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTMCK, ACT, MYLLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:00 EDTFOXAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTNDAQOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:23 EDTTWCUBS to hold a conference
42nd Annual Global Media & Communications Conference is being held in New York on December 8-10 with webcasted company presentations to begin on December 8 at 8 am; not all presentations may be webcasted. Webcast Link
05:58 EDTNDAQNASDAQ upgraded to Outperform from Market Perform at Keefe Bruyette
Subscribe for More Information
December 5, 2014
17:04 EDTVTRVentas files to sell 148,241 shares of common stock for holders
Subscribe for More Information
16:54 EDTFOXA21st Century Fox initiated with a Buy at UBS
Target $46.
16:49 EDTACTAdvisory Committee recommends approval Of Actavis' ceftazidime-avibactam
Actavis announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections and complicated urinary tract infections caused by Gram-negative pathogens. The committee found the scientific and clinical evidence submitted by Cerexa, a wholly owned subsidiary of Actavis, adequately demonstrated the safety and efficacy of ceftazidime-avibactam in the treatment of the proposed cIAI and cUTI indications. The committee voted not to recommend approval of the combination for hospital-acquired bacterial pneumonia /ventilator-associated bacterial pneumonia and bacteremia.The Advisory Committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for ceftazidime-avibactam during the first quarter of 2015.
10:22 EDTPFEBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:05 EDTPFE, MYLBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:56 EDTPFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
08:57 EDTSHLDSears risk/reward remains quite negative, says Evercore ISI
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use